New targeted pill combo for advanced colon or stomach cancers
Part of Cancer, Digestive system clinical trials.
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon (CRC) or stomach/gastroesophageal (EGC) adenocarcinoma that has spread or is locally advanced
- You’ve tried at least one prior treatment, and it either stopped working or you couldn’t tolerate it
- Your cancer has measurable tumors on scans (the study team must be able to track changes)
- You should be able to do daily activities fairly well (ECOG performance status 0–1)
- Your blood counts and organ tests must be in safe ranges (low hemoglobin/neutrophils/platelets, or major liver/kidney problems may exclude you)
- You must be able to swallow pills and agree to contraception if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hear when a new Locally Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.